Hepatic and Plasma Endothelin-1 in Dogs with Chronic Hepatitis

Area of Science:

• Veterinary Medicine
• Hepatology
• Endocrinology

Background:

• Endothelin-1 (ET-1) is a potent vasoactive peptide implicated in increased intrahepatic resistance in chronic hepatitis (CH) and cirrhosis.
• ET-1 concentrations have not been previously studied in dogs with CH.

Purpose of the Study:

• To compare hepatic and plasma ET-1 levels in healthy dogs versus dogs with CH.
• To investigate the relationship between plasma ET-1 levels and portal vein pressure in dogs with CH.

Main Methods:

• A prospective case-control study involving 14 healthy dogs and 20 dogs with CH.
• Hepatic ET-1 mRNA expression analyzed by real-time RT-PCR.
• Hepatic and plasma ET-1 protein levels measured by ELISA; splenic pulp pressure (SPP) assessed laparoscopically.

Main Results:

• Hepatic ET-1 mRNA levels were 3.7 times higher in dogs with CH (P = .008).
• Significantly elevated median hepatic and plasma ET-1 protein levels were observed in dogs with CH compared to healthy controls (P = .004 and P = .013, respectively).
• A weak but significant positive correlation was found between plasma ET-1 level and SPP in dogs with CH (P = .036, r_s = 0.53).

Conclusions:

• Elevated ET-1 in dogs with CH suggests its involvement in the pathogenesis of the condition.
• ET-1 may play a significant role in the development of portal hypertension secondary to chronic hepatitis in dogs.